Harvard Bioscience (HBIO) Amortization - Intangibles (2010 - 2026)

Harvard Bioscience (HBIO) has reported Amortization - Intangibles for 17 consecutive years, with $820000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Amortization - Intangibles fell 29.31% year-over-year to $820000.0; the TTM figure through Mar 2026 stood at $3.7 million (down 27.45% YoY), while the FY2025 annual figure was $4.0 million, down 23.37% from the prior year.
• Amortization - Intangibles declined to $820000.0 in Q1 2026 per HBIO's latest filing, from $850000.0 in the prior quarter.
• Across five years, Amortization - Intangibles topped out at $1.6 million in Q4 2022 and bottomed at $820000.0 in Q1 2026.
• Historically, Amortization - Intangibles has averaged $1.3 million across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2022 — Amortization - Intangibles climbed 11.11% — and 2025, when it tumbled 35.91%.
• Harvard Bioscience's Amortization - Intangibles stood at $1.6 million in 2022, then slipped by 13.31% to $1.4 million in 2023, then retreated by 9.37% to $1.3 million in 2024, then slumped by 32.38% to $850000.0 in 2025, then dropped by 3.53% to $820000.0 in 2026.
• Business Quant data shows HBIO's Amortization - Intangibles at $820000.0 in Q1 2026, $850000.0 in Q4 2025, and $855000.0 in Q3 2025.